Sign in

CIK 0001393434

  • Large accelerated filer

OCULAR THERAPEUTIX, INC

Sign in to watch
Ticker
OCUL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 781-357-4000
Business address
14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA, 01730
Former names
I-THERAPEUTIX INC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$799,174
in 9 filings, $788K under 10b5-1 plans

Net −$799,174. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-02-22 Dugel Pravin Executive Chairman Grant or award · Stock Option (Right to Buy) +1,282,469 1,282,469
2024-02-22 Nayak Sanjay Chief Strategy Officer Grant or award +80,300 180,300
2024-02-22 Nayak Sanjay Chief Strategy Officer Grant or award · Stock Option (Right to Buy) +244,550 244,550
2024-02-05 White Christopher G Chief Business Officer Sale +5,910 $4.86 $29K 123,689
2024-02-05 Strassburger Philip C. General Counsel Sale +6,029 $4.86 $29K 161,493
2024-02-05 Ozden Rabia Gurses Chief Medical Officer Sale +6,346 $4.86 $31K 153,054
2024-02-05 Notman Donald Chief Financial Officer Sale +6,212 $4.86 $30K 195,356
2024-02-05 Mattessich Antony C. President and CEO Sale +19,642 $4.86 $95K 588,701
2024-02-03 White Christopher G Chief Business Officer Grant or award +39,980 129,599
2024-02-03 White Christopher G Chief Business Officer Grant or award · Stock Option (Right to Buy) +120,000 120,000
2024-02-03 Strassburger Philip C. General Counsel Grant or award +58,304 167,522
2024-02-03 Strassburger Philip C. General Counsel Grant or award · Stock Option (Right to Buy) +175,000 175,000
2024-02-03 Ozden Rabia Gurses Chief Medical Officer Grant or award +66,633 159,400
2024-02-03 Ozden Rabia Gurses Chief Medical Officer Grant or award · Stock Option (Right to Buy) +200,000 200,000
2024-02-03 Notman Donald Chief Financial Officer Grant or award +61,636 201,568
2024-02-03 Notman Donald Chief Financial Officer Grant or award · Stock Option (Right to Buy) +185,000 185,000
2024-02-03 Mattessich Antony C. President and CEO Grant or award +180,400 608,343
2024-02-03 Mattessich Antony C. President and CEO Grant or award · Stock Option (Right to Buy) +549,400 549,400
2024-01-31 Notman Donald Chief Financial Officer Sale −6,433 $4.95 $32K 139,932
2024-01-31 Ozden Rabia Gurses Chief Medical Officer Sale −7,764 $4.95 $38K 92,767

Page 9 of 17 · 327 trades